ALT
Price
$2.75
Change
-$0.10 (-3.50%)
Updated
Oct 1, 01:21 PM (EDT)
Capitalization
575.77M
40 days until earnings call
Intraday BUY SELL Signals
GALT
Price
$3.80
Change
-$0.08 (-2.06%)
Updated
Oct 1, 01:50 PM (EDT)
Capitalization
396.34M
46 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALT vs GALT

ALT vs GALT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALT vs. GALT commentary
Oct 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a StrongBuy and GALT is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ALT vs GALT: Fundamental Ratings
ALT
GALT
OUTLOOK RATING
1..100
2987
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
7146
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GALT's Valuation (92) in the Biotechnology industry is in the same range as ALT (94) in the Miscellaneous Commercial Services industry. This means that GALT’s stock grew similarly to ALT’s over the last 12 months.

GALT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that GALT’s stock grew similarly to ALT’s over the last 12 months.

ALT's SMR Rating (96) in the Miscellaneous Commercial Services industry is in the same range as GALT (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to GALT’s over the last 12 months.

GALT's Price Growth Rating (46) in the Biotechnology industry is in the same range as ALT (71) in the Miscellaneous Commercial Services industry. This means that GALT’s stock grew similarly to ALT’s over the last 12 months.

GALT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that GALT’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTGALT
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
COMPARISON
Comparison
Oct 01, 2026
Stock price -- (ALT: $2.86 vs. GALT: $3.88)
Brand notoriety: ALT and GALT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 107% vs. GALT: 59%
Market capitalization -- ALT: $575.77M vs. GALT: $396.34M
ALT [@Biotechnology] is valued at $575.77M. GALT’s [@Biotechnology] market capitalization is $396.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green while GALT’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • GALT’s FA Score: 0 green, 5 red.
According to our system of comparison, GALT is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 4 TA indicator(s) are bullish while GALT’s TA Score has 6 bullish TA indicator(s).

  • ALT’s TA Score: 4 bullish, 4 bearish.
  • GALT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GALT is a better buy in the short-term than ALT.

Price Growth

ALT (@Biotechnology) experienced а -10.34% price change this week, while GALT (@Biotechnology) price change was -4.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.32%. For the same industry, the average monthly price growth was -11.90%, and the average quarterly price growth was -0.35%.

Reported Earning Dates

ALT is expected to report earnings on Nov 10, 2026.

GALT is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Biotechnology (-3.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ALT
Daily Signal:
Gain/Loss:
GALT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NA2.210.04
+1.84%
Nano Labs Ltd
KBONU10.30N/A
N/A
Karbon Capital Partners Corp
NBHC39.19-0.04
-0.10%
NATIONAL BANK HOLDINGS Corp
TSBK44.58-0.30
-0.67%
Timberland Bancorp
TGTX55.78-0.41
-0.73%
TG Therapeutics